The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...
The combination met its primary endpoint of percent weight loss following an 8-week treatment period.
Oral PCSK9 inhibitor, AZD0780, demonstrated a significant 50.7% reduction in LDL cholesterol levels in the Phase IIb PURSUIT ...
Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and ...
Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...
Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.
In this video interview, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), highlights how recent funding cuts are impacting critical research resources.
In this video interview, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), discusses how the current political climate is affecting diversity in clinical research and how ...
Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.
Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to ...
Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention ...
In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, discusses findings from the report and the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback